达格列净联合常规降糖药治疗2型糖尿病血糖控制未达标患者的临床观察  

Clinical observation of dapagliflozin combined with conventional hypoglycemic drugs on substandard glycemic control of type 2 diabetic patients

作　　者：张帆 陈怀宁[1] 张亚楠 ZHANG Fan;CHEN Huai-ning;ZHANG Ya-nan(Beijing Chaoyang District Jinsong Community Health Service Center,Beijing 100021,China)

机构地区：[1]北京市朝阳区劲松社区卫生服务中心,北京100021

出　　处：《中国处方药》2023年第9期141-144,共4页Journal of China Prescription Drug

摘　　要：目的观察达格列净联合常规降糖治疗血糖控制未达标的2型糖尿病(T2DM)患者的疗效和安全性。方法收集2021年7月~2022年1月北京市朝阳区劲松社区卫生服务中心就诊的应用常规降糖药治疗但未曾使用钠-葡萄糖协同转运蛋白-2抑制剂(SGLT-2i)类药物且血糖控制不达标的260例T2DM患者作为研究对象,在原有降糖方案基础上加用达格列净治疗并且连续治疗12周,观察比较加用前后相关指标变化。且为进一步观察联合治疗对肾功能、血压及体重指数的影响,将患者分为正常组和异常组,比较两组治疗前后尿微量白蛋白、收缩压(SBP)、舒张压(DBP)水平及体重指数(BMI)。结果经治疗12周后,空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbAlc)达标率、BMI及高血压组的SBP、DBP等指标均较治疗前改善,差异有统计学意义(P<0.05)。治疗后不良反应主要表现为泌尿系感染及低血糖反应。结论对于应用常规降糖药物治疗血糖控制未达标的2型糖尿病患者,加用达格列净后可显著降低其血糖、糖化血红蛋白水平,并在一定程度上降低血压、BMI。除个别泌尿系感染及低血糖反应情况外,未见其他不良反应发生,安全性较高。Objective To observe the efficacy and safety of dapagliflozin combined with conventional hypoglycemic therapy in patients with type 2 diabetes mellitus(T2DM)whose glycemic control did not reach the standard.Methods Collect 260 T2DM patients treated with conventional hypoglycemic drugs but without SGLT-2i class drugs and with inadequate blood sugar control from July 2021 to January 2022 at Beijing Chaoyang District Jinsong Community Health Service Center as the research subjects.On the basis of the original hypoglycemic regimen,add dapagliflozin for treatment and continuously treat for 12 weeks.Observed and compared the changes in relevant indicators before and after the addition.To further observe the effects of combined therapy on renal function,blood pressure,and body mass index,patients were divided into normal and abnormal groups.Urinary microalbumin,systolic blood pressure(SBP),diastolic blood pressure(DBP)levels,and body mass index(BMI)were compared before and after treatment between the two groups.Results After 12 weeks of treatment,the fasting blood glucose(FPG),2-hour postprandial blood glucose(2 hPG),glycated hemoglobin(HbAlc)compliance rate,body mass index(BMI),and systolic blood pressure(SBP)and diastolic blood pressure(DBP)in the hypertension group were all improved than before treatment,with statistically significant differences(P<0.05).The main adverse reactions after treatment are urinary tract infections and hypoglycemic reactions.Conclusion For patients with type 2 diabetes whose blood sugar control is not up to the standard by using conventional hypoglycemic drugs,the addition of dapagliflozin can significantly reduce their blood sugar,glycosylated hemoglobin levels,and to a certain extent,reduce blood pressure and BMI.Except for individual urinary tract infections and hypoglycemic reactions,no other adverse reactions were observed,indicating high safety.

关 键 词：达格列净 2型糖尿病 药物治疗 

分 类 号：R587.1[医药卫生—内分泌]